Obeldesivir, Q55KCM7PXB, ATV006, CAS 2647441-36-7 for COVID-19

Views : 39
Author : sarms4muscle
Update time : 2024-05-24 10:53:23
Drug name: Obeldesivir

Code: Q55KCM7PXB; ATV006
CAS: 2647441-36-7
Indication: COVID-19
Development stage: Phase 3

Obeldesivir (currently in phase 3 clinical trials for the treatment of COVID-19) has therapeutic value for the treatment of filoviruses in non-human primates. Administered once daily for 10 days within 24 hours of exposure to the virus, the drug completely protects animals from lethal infection by Sudanese viruses.

Effectiveness of Obeldesivir against Sudan virus
Obeldesivir administered orally once a day was completely protective in crab-eating monkeys within 10 days of Sudan virus infection and in 60% of animals within 5 days of infection. Successful Obeldesivir treatment delayed or prevented the onset of disease, inhibited viral replication, prevented immune dysregulation and coagulation abnormalities, and thereby promoted lymphocyte activation and the production of anti-Sudan virus antibodies.